S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
North Carolina medical marijuana sales begin at Cherokee store
Ukrainian and Western leaders laud US aid package while the Kremlin warns of 'further ruin'
Hawaii lawmakers take aim at vacation rentals after Lahaina wildfire amplifies Maui housing crisis
Biden sees a $35 price cap for insulin as a pivotal campaign issue. It’s not that clear-cut
Autoworkers union celebrates breakthrough win in Tennessee and takes aim at more plants in the South
'Civil War’ continues box-office campaign at No. 1
New York lawmakers pass $237 billion budget with policies to jump-start housing market

Omeros (OMER) Stock Forecast & Price Target

$3.05
-0.16 (-4.98%)
(As of 04/19/2024 ET)

Omeros Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 1 Analyst Ratings

Analysts' Consensus Price Target

N/A

TypeCurrent Forecast
4/22/23 to 4/21/24
1 Month Ago
3/23/23 to 3/22/24
3 Months Ago
1/22/23 to 1/22/24
1 Year Ago
4/22/22 to 4/22/23
Consensus Rating
Hold
Hold
Hold
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price TargetN/AN/AN/A$8.00
Predicted UpsideN/AN/AN/A163.74% Upside
Get Omeros Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

OMER Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OMER Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Omeros Stock vs. The Competition

TypeOmerosMedical CompaniesS&P 500
Consensus Rating Score
2.00
2.68
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside1,022.47% Upside11.95% Upside
News Sentiment RatingPositive News
Neutral News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/10/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
O. Brayer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 02:35 PM ET.

OMER Price Target - Frequently Asked Questions

What is Omeros's consensus rating?

According to the issued ratings of 1 analysts in the last year, the consensus rating for Omeros stock is Hold based on the current 1 hold rating for OMERthe . Learn more on OMER's analyst rating history.

Do Wall Street analysts like Omeros more than its competitors?

Analysts like Omeros less than other Medical companies. The consensus rating for Omeros is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how OMER compares to other companies.


Stock Ratings Reports and Tools

This page (NASDAQ:OMER) was last updated on 4/21/2024 by MarketBeat.com Staff

From Our Partners